Federal Register Notice: FDA has determined the regulatory review period for Shire’s Fosrenol is 2,449 days for the extending a patent which claims the human drug product. Fosrenol (lanthanum carbonate hydrate) is indicated to reduce serum phosphate in patients with end stage renal disease. To view this notice, click here.
